logo-loader
viewCo-Diagnostics

Wainwright reiterates ‘Buy’ rating on Co-Diagnostics as US domestic coronavirus cases surge boosting testing demand

Analysts Yi Chen and Raghuram Selvaraju also reiterated their $35 price target on the Utah-based company’s stock

Co-Diagnostics - Wainwright reiterates ‘Buy’ rating on Co-Diagnostics Inc as US domestic coronavirus cases surge boosting testing demand
According to the analysts, the company had approximately $100 million worth of Logix Smart COVID-19 test kits in mid-May that were slated to be shipped

Analysts at Wainwright reiterated their “Buy” rating on Co-Diagnostics Inc (NASDAQ:CODX) as US domestic coronavirus cases surged boosting demand for the company's coronavirus (COVD-19) diagnostic test.

“As reported in the Wall Street Journal yesterday, the COVID-19 testing system is reaching the brink in the US as growing demand surpasses what the nation’s labs can handle, resulting in supply shortages and backlogs,” wrote Wainwright analysts Yi Chen and Raghuram Selvaraju.

“Outside the US, Brazil, India, and South Africa are registering the greatest rises in COVID-19 cases, according to the United Nations health agency. Therefore, we believe Co-Diagnostics should continue to ship a high volume of its Logix Smart COVID-19 test kits, with an increasing volume shipped to U.S. customers.”

READ: Co-Diagnostics stock gains after Litchfield Research doubles its price target on coronavirus test sales

In addition, the large India market is serviced by the Utah-based company's joint venture, CoSara, with manufacturing facilities located in India. The analysts noted that sales of CoSara have yet to be integrated into the company’s topline revenue.

According to the analysts, the company had approximately $100 million worth of tests in mid-May that were slated to be shipped.

“In the wake of the accelerating COVID-19 spread, we reiterate our ‘Buy’ rating and $35 price target,” said the analysts.

Wainwright also pointed out that the company’s Logix Smart COVID-19 test’s high accuracy has been independently validated by PathWest Laboratories in Australia, the Indian National Institute of Pathology, and the Mexican Department of Epidemiology.

Co-Diagnostics' stock, which has been one of the hottest on Wall Street during the last two months, recently rose 1.51% to $18.46 in afternoon trading.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Co-Diagnostics

Price: 27.62 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $758.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read